; Stolt, CC. 32:783. doi: 10.1200/jco.2013.49.3726, Calatozzolo, C., Pollo, B., Botturi, A., Dinapoli, L., Carosi, M., Salmaggi, A., et al. The growth of cells, called a tumor, begins in cells called oligodendrocytes. 0000226081 00000 n 79, 153157. doi: 10.1111/nan.12088. J. Biol. It is believed that anaplastic oligodendroglioma (AO) can progress from a lower grade oligodendroglioma after the acquisition of specific genetic alterations (Youssef and Miller, 2020). In giant cells gliomas, giant cells were GFAP negative or weakly positive. J. Neurosurg. . Sagittal gadolinium-enhanced T1-weighted magnetic resonance image of a low-grade oligodendroglioma. Jain SU, Do TJ, Lund PJ, et al. Additionally, the mTOR pathway has been identified at a potential target for treatment due its activation in IDH-mutant gliomas. Upon surgical debulking and pathological diagnosis, he was found to have recurrent diseases. 56-64. 0000245612 00000 n Biochim. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. J. Clin. Genetic alterations and signaling pathways in the evolution of gliomas. ; Mork, S.; Graeber, MB. Giannini, C.; Scheithauer, BW. (2003). This means it begins in the brain or spinal cord. Patients with co-deleted tumors demonstrate favorable prognoses (Smith et al., 2000a; Ino et al., 2001; Cairncross et al., 2006; Kaloshi et al., 2007; Cairncross et al., 2013). Douglas E Ney, MD is a member of the following medical societies: American Academy of Neurology, American Society of Clinical Oncology, Society for Neuro-OncologyDisclosure: Nothing to disclose. Copyright 2021 Bou Zerdan and Assi. Survey of treatment recommendations for anaplastic oligodendroglioma. While usually unexpressed in mature cells, cancer cells make use of this enzyme to promote their survival and increase proliferation. ; Hernndez-Lan, A. et al. (1994) and showed that the median time to progression for patients was at least 25.2 months for complete responders, 14.2 months for partial responders and 6.8 months for stable patients. 0000141681 00000 n Oligodendroglial tumors. Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Two of 10 central neurocytomas and 2/10 clear cell ependymomas showed focal OLIG2 expression. J. Clin. Focused Oligodendroglioma with stained slides of pathology. Oligodendroglioma, IDH mutant and 1p/19q codeleted is CNS tumour that is typically in the cerebral hemispheres. 13, 20662071. PCV and TMZ are also used in cases of recurrence but result in lower response rates and disease-free survival. The wildtype (WT) TERT group was associated with good prognosis only in IDH1/IDH2 WT (IDH-WT) grade II/III astrocytomas. J. Neurooncol. Acta Neuropathol. For patients with WHO grade 2 and KPS 60, the majority (90.5% . Elens et al. 0000004863 00000 n NCI CPTC Antibody Characterization Program, Agnihotri S, Aldape KD, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Jaeckle, K. A., Ballman, K. V., van den Bent, M., Giannini, C., Galanis, E., Brown, P. D., et al. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, WHO CNS Grade 2 (ICD-O: 9450/3). Oligodendrogliomas. Epub 2011 Nov 10. doi: 10.1007/BF00177439, Mason, W. P., Krol, G. S., and DeAngelis, L. M. (1996). 0000124516 00000 n Symptomatic spinal cord metastasis from cerebral oligodendroglioma. [QxMD MEDLINE Link]. 12,142 Images : Last Update : Apr 23, 2023. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. (1996). Similarly in a retrospective study by Fujii et al. These alterations have correlated with a shorter event free survival (EFS; 29 vs. 53 months, p < 0.0001) and OS (48 vs. 83 months, p < 0.0001). (2016). doi: 10.1371/journal.pone.0068782, Keywords: anaplastic oligodendroglioma, PCV, IDH mutation, procarbazine, lomustine, vincristine, temozolomide, Citation: Bou Zerdan M and Assi HI (2021) Oligodendroglioma: A Review of Management and Pathways. doi: 10.1038/nature10860, Luyken, C., Blmcke, I., Fimmers, R., Urbach, H., Elger, C. E., Wiestler, O. D., et al. Neurosurgery 43, 10661073. Natl. This co-deletion, along with the IDH mutation, enables a tumor to be classified as an oligodendroglioma according to the WHO 2016 criteria (Louis et al., 2016). This previously diagnosed oligoastrocytoma, WHO grade II (. 138, 915924. Another factor that increases probability of survival in low-grade gliomas is a high performance status. NCT04708548 is an ongoing European cross-sectional study that is looking at health-related quality of parameters and outcomes in survivors after being treated with surgery, chemotherapy and/or RT. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Commun. 1994. Anaplastic oligodendroglioma. 10, 139144. J. Neurosci. 44(Suppl 2):A262-A263. MB drafted the manuscript and contributed to the discussion section. Oligodendrogliomas. [QxMD MEDLINE Link]. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of -ketoglutarate-dependent dioxygenases. These tumors are genetically defined according to the mutations they harbor. For nearly a century, the diagnosis and grading of oligodendrogliomas and oligoastrocytomas has been based on histopathology alone. 0000351419 00000 n ; Tihan, T.; Lin, D.; McDonald, W.; Nigro, J.; Feuerstein, B.; Jackson, S.; Cohen, K. et al. Cancer Interdiscipl. Infiltration of immune cells, specifically T cells, were also reduced in these tumors (Amankulor et al., 2017; Kohanbash et al., 2017). [QxMD MEDLINE Link]. (2015). Oligodendrogliomas are grouped in two grades based on their characteristics. Abstract Aims: We performed an immunohistochemical analysis of alpha-thalassaemia/mental retardation syndrome X-linked (ATRX) expression in adult diffuse gliomas, with reference to clinicopathological and genetic features, to determine the utility of this analysis in diagnostic practice. 2013;23:454461. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. doi: 10.3171/2017.3.JNS162383, Fulton, D., Urtasun, R., and Forsyth, P. (1996). IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. There are 11 ongoing clinical trials recruiting patients with AO. Cancer. Mutant IDH1 has also been shown to inhibit the ALkB family DNA repair enzymes further contributing to erroneous DNA replication (Wang et al., 2015; Rinaldi et al., 2016). This tumor, previously diagnosed, Example where molecular reclassification does, Example where molecular reclassification does not affect tumor grade. [QxMD MEDLINE Link]. 19, 24492455. Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine. 1995. National Cancer Institute. Some of these alterations have correlated with prognosis and response to treatment. 123, 853860. 2020 May 15. Nature 483, 479483. Oligodendrogliomas rarely spread outside of the CNS to other organs. doi: 10.12786/bn.2022.15.e23. PDF CORE - Aggregating the world's open access research papers Stephen A Berman, MD, PhD, MBA Professor of Neurology, University of Central Florida College of Medicine Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. ROS and brain gliomas: an overview of potential and innovative therapeutic strategies. Kaye AH, Laws ER Jr, eds. Clinical trials, with new chemotherapy, targeted therapy, or immunotherapy drugs, may also be available and can be a possible treatment option. 18, 15291537. Am. Intravenous carboplatin for recurrent malignant glioma: a phase II study. Eight of 10 central neurocytomas, all clear cell meningiomas and 8/10 clear cell ependymomas were negative for OLIG2. Clinical features, diagnosis, and pathology of IDH-mutant - UpToDate 0000015702 00000 n This comes with a risk of sacrificing important brain centers and hence compromising functionality and quality of life. All oligodendroglial neoplasms and DNTs showed widespread OLIG2 expression. (2012). PLoS One 11:e0163067. . NCT01849952 is another clinical trial that will evaluate the expression levels of microRNA-10b in patients with AO, although it will not involve any new therapeutic regimens. J. Neurosurg. Pharm. Therefore, PTEN is a target of 10q loss, and PTEN alterations are associated with aggressive tumor phenotypes regardless of chemosensitivity (Sasaki et al., 2001). Some oligodendrogliomas have eosinophilic cytoplasm with focal perinuclear clearing. Pediatric oligodendroglioma is a low-grade glioma that remains relatively rare when compared to adults. Epilepsia 44, 822830. Careers. The Spectrum of Long-term Epilepsyassociated Tumors: Long-term Seizure and Tumor Outcome and Neurosurgical Aspects. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. doi: 10.1007/s11060-012-0946-9, Carbonneau, M., Gagn, L. M., Lalonde, M.-E., Germain, M.-A., Motorina, A., Guiot, M.-C., et al. doi: 10.1093/jnen/59.6.495, Smits, A., and Duffau, H. (2011). A., Taphoorn, M. J., Wesseling, P., et al. ; Bauserman, S. et al. Lower grade gliomas. More studies, however, are needed to explore molecular pathways in oligodendroglioma and AO specifically after the 2016 classification. Oligodendrogliomas are tumors that develop from a certain type of cell called oligodendroglial progenitor cells. National Cancer Institute of Canada Clinical Trials Group. Chem. Some subtypes +ve - should not be used to distinguish. Recently, 1p/19q codeletion was independently validated as a favorable prognostic factor in low grade glioma.{ref35. J Neurooncol. 366(9490):985-90. 0000222846 00000 n 0000226003 00000 n IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. doi: 10.1093/neuonc/noaa168, Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. The earliest regimen used for the treatment of these tumors was procarbazine, lomustine, and vincristine. for: Medscape. (2018) conducted a Surveillance, Epidemiology, and End Results (SEER)-based analysis in 2017 and showed that GTR was not associated with improved survival in patients with WHO grade II and grade III oligodendrogliomas compared to patients with anaplastic astrocytomas and glioblastomas. 0000015277 00000 n Elsewhere, another phase 1 study (NCT02644291) is assessing the use of mebendazole in recurrent/progressive pediatric brain tumors of 21 participants. Mason WP. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. 0000018446 00000 n Roger E McLendon, MD Professor, Director of Surgical Pathology, Chief of Neuropathology, Department of Pathology, Duke University Medical Center Englot, D. J., Berger, M. S., Barbaro, N. M., and Chang, E. F. (2011). The .gov means its official. Recent advances in molecular profiling technology, including comprehensive DNA sequencing A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Epileptogenic tumors affecting children and young adults are a morphologically diverse collection of neuroepithelial neoplasms that, as a group, exhibit varying levels of glial and/or neuronal differentiation. Boston: Butterworth Heinemann; 1997. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. California: University of California. Cancer 91, 417422. Polymorphous low-grade neuroepithelial tumor of the young - PubMed In a population of patients with oligodendroglial tumors, four cases exhibited absent CIC expression with no detectable mutations, suggesting that alterations affecting CIC could occur through other unidentified mechanisms (Chan et al., 2014). Tork, C. A., and Atkinson, C. (2020). Oligodendrogliomas are molecularly defined by the presence of complete deletion of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) (1p/19q co-deletion). Nat. 0000008234 00000 n J. Clin. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Megyesi JF, Kachur E, Lee DH, et al. doi: 10.1101/gad.294991.116, Ascierto, P. A., McArthur, G. A., Drno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., et al. Scholarly Res. In practice, (neuro)pathologists who readily accept the existence of mixed gliomas will more liberally diagnose oligoastrocytomas, while those who are skeptical that this entity exists will designate the vast majority of diffuse gliomas as either astrocytic or oligodendroglial (, Example of how molecular reclassification may affect tumor grade. "Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.". All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Oligodendroglioma High Quality Pathology Images of Neuropath: Glial Tumors of Oligodendroglioma . (Feb 2007). High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Extraneural metastases of anaplastic oligodendroglioma. In a subgroup analysis, oligodendroglioma diagnosis was a favorable prognostic factor resulting in increased overall and progression-free survival; however, oligodendrogliomas were classified histologically in this study, not by 1p/19q status. doi: 10.1101/gad.13.12.1501. *Correspondence: Hazem I. Assi, [email protected], https://doi.org/10.3389/fnmol.2021.722396, Creative Commons Attribution License (CC BY), Division of Hematology and Oncology, Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon. Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell. doi: 10.1097/00006123-199811000-00035, Taliansky-Aronov, A., Bokstein, F., Lavon, I., and Siegal, T. (2006). The end result is DNA hypermethylation and thus the blockage of cellular differentiation (Kaminska et al., 2019). (2019). [3] This risk classification may change in the future as our understanding of the contributions of genetic markers to survivability evolves. This means it begins in the brain or spinal cord. Bettegowda, C. (2000). Adekunle M Adesina, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Neuropathologists, College of American Pathologists, United States and Canadian Academy of PathologyDisclosure: Nothing to disclose. Molecular alterations associated with tumor progression: Glioma CpG island methylator phenotype (G CIMP) (. 31, 15881604. Pediatric oligodendroglioma is a low-grade glioma that remains relatively rare when compared to adults. Neurol India. Analysis from the initial study design. Arch Pathol Lab Med 131:242251. doi: 10.1200/jco.2003.06.023. 2003 Jul 1. 97, 23812386. Widespread dissemination in a gliomatosis cerebri fashion is very rare (DDx: Diffuse leptomeningeal glioneuronal tumour). (2001) reported that 16.7% of patients experienced a complete response and 27.1% experienced a partial response when receiving temozolomide (TMZ) after previous PCV. Each stratum has different combination treatments and targeted patient populations. (2013) was the first to conduct a meta-analysis on PFS and OS in gliomas based on IDH mutations. [QxMD MEDLINE Link]. This was attributed to the sensitivity of oligodendrogliomas to chemotherapy compared to astrocytomas (Alattar et al., 2018). doi: 10.1016/j.ccr.2010.12.014, Yip, S., Butterfield, Y. S., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., et al. 0000001996 00000 n Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug ReferenceDisclosure: Received salary from Medscape for employment. Weinberg, R. A. 0000276291 00000 n Prominent anaplastic features (necrosis, microvascular proliferation or brisk mitotic activity) are compatible with anaplastic oligodendroglioma, Strict mitotic activity criteria do not currently exist, Some authors suggest 6 mitotic figures per 10 high power fields in resection specimens for grade 3 designation (, Fewer mitotic figures might be sufficient for grade 3 designation in small biopsy specimens if other anaplastic features (vascular proliferation or necrosis) or significant nuclear atypia are present, Magnetic resonance imaging (MRI), followed by stereotactic brain biopsy or surgical resection, Immunohistochemistry for IDH1 R132H (positive in > 90% of tumors) (, Droplet digital polymerase chain reaction (ddPCR), MRI techniques to detect 2-hydroxyglutarate and therefore, Mixed density (hypodense and isodense) located in cortex or subcortical white matter (, High attenuation areas, likely from calcifications, Heterogeneous on T1 and T2 weighted imaging, Contrast enhancement present in < 20% of WHO grade 2 tumors and > 70% of WHO grade 3 tumors (, Elevated 2HG by magnetic resonance spectroscopy could serve as radiologic surrogate of, Slow growing and relatively long overall survival, Median overall survival: 11.6 years; 10 year overall survival rate: 51 - 63% (, Longer median survival compared with grade 2, Macroscopically complete surgical resection, Local recurrence and malignant transformation are common, 26 year old man presents with nausea, headache and rash (, 43 year old woman with headaches, blurry vision and a right parietal mass (, 44 year old man with sudden right sided optic neuritis (, 55 year old man with mass lesion in the superior left temporal gyrus (, Adjuvant chemotherapy (temozolomide) and radiotherapy, Given to patients with symptomatic or progressive tumors, tumors with CNS WHO grade 3 histology or those with large postoperative residual tumor, Mucoid change can give a gelatinous consistency, Areas of cystic degeneration, calcifications, hemorrhage or necrosis can be seen, Moderately cellular, diffusely infiltrating neoplasm, Glia with mild to moderate nuclear atypia, Calcifications, perineuronal satellitosis or perivascular accumulation of tumor cells may be seen, Will not see perinuclear halos on frozen section or smear preparations, Anaplastic features (necrosis, vascular proliferation, mitoses) may be seen in WHO grade 3 tumors, Closely packed cells with small, round, monotonous nuclei (slightly larger than a normal oligodendrocyte), Perinuclear clearing (fried egg appearance), Will not be seen on frozen sections or smear preparations, Network of thin walled, branching blood vessels (chicken wire vasculature), Microcalcifications (calcospherites) are characteristic, Presence of perineural, perivascular or subpial aggregates of tumor cells (secondary structures of Scherer), Occasional mitoses and moderate nuclear atypia are still consistent with grade 2 designation (, Not uncommon to find well differentiated / fibrillary astrocytic morphology (. Pembrolizumab Monotherapy Effective for Rare Melanoma, For Uninsured People With Cancer, Securing Care Can Be Like Spinning a Roulette Wheel, Nonmelanoma Skin Cancers You Need to Know. 0000005528 00000 n However, a clear distinction of both grades is not always possible. All of the cases have completed central pathological review and met the PLNTY criteria of the following: 1) infiltrative and nodular growth pattern; 2) invariable presence of oligodendroglioma-like cellular component with more or less polymorphic cellular elements including pleomorphic and spindle cells; 3) intense immunolabeling for cluster of 0000004228 00000 n For example, a test may look at the changes in the tumor cells' genetic material, called DNA. 23 (3):457-467. (1995). Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A. J. Clin. Neurology. Your care team uses this information to create a treatment plan. Despite utilizing a multimodal approach in nearly all patients, refractory seizures can still be seen in patients suffering from epilepsy in 50% of the cases before the initial surgery and 1540% of cases following surgery and anticonvulsant therapy (Smits and Duffau, 2011; You et al., 2011; Calatozzolo et al., 2012). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Paleologos NA, Vick NA, Kachoris JP. 0000247714 00000 n Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications.